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Abstract
The left ventricular assist device was originally designed to be surgically implanted as a bridge to
transplantation for patients with chronic end-stage heart failure. On the basis of the REMATCH trial, the
US Food and Drug Administration and the US Centers for Medicare & Medicaid Services approved
permanent implantation of the left ventricular assist device as a destination therapy in Medicare
beneficiaries who are not candidates for heart transplantation. The use of the left ventricular assist device
as a destination therapy raises certain ethical challenges. Left ventricular assist devices can prolong the
survival of average recipients compared with optimal medical management of chronic end-stage heart
failure. However, the overall quality of life can be adversely affected in some recipients because of serious
infections, neurologic complications, and device malfunction. Left ventricular assist devices alter end-of-life
trajectories. The caregivers of recipients may experience significant burden (e.g., poor physical health,
depression, anxiety, and posttraumatic stress disorder) from destination therapy with left ventricular assist
devices. There are also social and financial ramifications for recipients and their families. We advocate early
utilization of a palliative care approach and outline prerequisite conditions so that consenting for the use
of a left ventricular assist device as a destination therapy is a well informed process. These conditions
include: (1) direct participation of a multidisciplinary care team, including palliative care specialists, (2) a
concise plan of care for anticipated device-related complications, (3) careful surveillance and counseling
for caregiver burden, (4) advance-care planning for anticipated end-of-life trajectories and timing of device
deactivation, and (5) a plan to address the long-term financial burden on patients, families, and caregivers.
Short-term mechanical circulatory devices (e.g. percutaneous cardiopulmonary bypass, percutaneous
ventricular assist devices, etc.) can be initiated in emergency situations as a bridge to permanent
implantation of ventricular assist devices in chronic end-stage heart failure. In the absence of first-person
(patient) consent, presumed consent or surrogate consent should be used cautiously for the initiation of
short-term mechanical circulatory devices in emergency situations as a bridge to permanent implantation
of left ventricular assist devices. Future clinical studies of destination therapy with left ventricular assist
devices should include measures of recipients' quality of end-of-life care and caregivers' burden.
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Introduction
In clinical practice, several types of mechanical circulatory
devices are used for the temporary support of the left or
right heart functions or both [1-6]. The left ventricular
assist device (LVAD) is a surgically implanted mechanical
circulatory device used for temporary support of left heart
function as a bridge to recovery of native function or to
cardiac transplantation [7-9]. However, it is becoming
increasingly common for the LVAD technology to be also
used as a permanent destination therapy (DT) for patients
with chronic end-stage heart failure who are not candi-
dates for transplantation [10]. Using LVAD technology as
DT (LVAD-DT) is intended to prolong survival, improve
quality of life (QOL) and enhance functional status of
patients with chronic end-stage heart failure. The benefits
attributed to LVAD-DT are substantiated by outcome data
obtained from several clinical studies [11-14]. In this arti-
cle, we re-examine survival data and common types of
complications attributed to LVAD-DT from the same clin-
ical studies in chronic end-stage heart failure.
The complications of LVAD-DT can adversely influence
QOL for patients and caregivers (e.g., spouses, adult chil-
dren or grand-children, significant others, and close
friends) alike and alter end-of-life trajectory in chronic
end-stage heart failure. Therefore, the use of LVAD-DT
raises certain ethical challenges that ought to be ade-
quately addressed in clinical practice. The ethical chal-
lenges pertain to the risks and benefits of such devices and
their consequences for end-of-life trajectories and care. To
address these ethical challenges, we describe prerequisite
conditions in the consent process for LVAD-DT to fulfill
the goals of patient-centered and optimal end-of-life care,
including palliation in patients who may choose LVAD-
DT as an alternate therapy option, in chronic end-stage
heart failure.
Device implantation and survival
LVAD implantation involves open heart surgery (Figure 1,
and additional file 1: videos of HeartMate XVE and
Thoratec ventricular assist devices implantation proce-
dures). Surgery to implant the LVAD has a hospital (30- to
90-day) mortality of 14% to 27%, depending on the recip-
ient's age and preexisting disease and comorbid condi-
tions [11-13,15,16]. In a prospective, randomized,
controlled trial (Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure
[REMATCH]) conducted between May 1998 and July
2001, 129 patients with chronic end-stage heart failure
who were ineligible for cardiac transplantation were ran-
domly assigned to receive LVAD-DT (n = 68) or optimal
medical management (OMM) (n = 61) [11]. In this trial,
the HeartMate XVE (Thoratec Corporation, Pleasanton,
California) was implanted as LVAD-DT (Figure 1) [1]. The
LVAD-DT group had superior survival over OMM at 1 year
follow-up (52% vs 25%, P = 0.002) and at 2-year (23% vs
8%,  P  = 0.09). However, the preponderance of male
patients enrolled in the REMATCH trial (82% and 78%
male patients treated with OMM and LVAD-DT, respec-
tively) made it difficult to generalize the survival benefits
to female patients [11]. In spite of this limitation of the
REMATCH trial, the US Food and Drug Administration
and the US Centers for Medicare & Medicaid Services
approved LVAD-DT in 2003 for men and women Medi-
care beneficiaries with chronic end-stage heart failure
[17,18].
The Centers for Medicare & Medicaid Services guidelines
for LVAD-DT eligibility in patients with chronic end-stage
heart failure (New York Heart Association class IV end-
stage left ventricular failure for ≤ 90 days with a life expect-
ancy of < 2 years) and are not candidates for heart trans-
plantation, mandate that they must meet all of the
following conditions:
(1) The patient's class IV heart failure symptoms have
failed to respond to OMM, including dietary salt restric-
tion, diuretics, digitalis, β-adrenergic receptor-blocking
agents, and angiotensin-converting enzyme inhibitors (if
tolerated) for at least 60 of the past 90 days.
(2) The patient has a left ventricular ejection fraction of
less than 25%.
(3) The patient has demonstrated functional limitation,
with a peak oxygen consumption of less than 12 mL/kg
per minute or the patient has continued need for intrave-
nously administered inotropic therapy because of symp-
tomatic hypotension, decreasing renal function, or
worsening pulmonary congestion.
(4) The patient has the appropriate body surface area or
size (≥ 1.5 m2) to support implantation of the ventricular
assist device [17-19].
Notably, these coverage criteria do not address or stipulate
several factors (e.g., cachexia, right ventricular heart fail-
ure, pulmonary hypertension, concurrent end-organ dis-
ease, malignancy or psychosocial factors) that are critical
to patient outcome and QOL. Nevertheless, considering
these factors is important in order to avoid, in some cases,
reaching an ethically complex end-point sometimes
referred to as "destination nowhere." [20].
In the INTrEPID trial (Chronic Mechanical Circulatory
Support for Inotrope-Dependent Heart Failure Patients
Who Are Not Transplant Candidates) conducted between
March 2000 and May 2003, the Novacor device (World
Heart Corp, Oakland, California) was used in LVAD-DT
patients [12]. The survival rates for LVAD-DT (n = 37) andPhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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The left ventricular assist device (LVAD) Figure 1
The left ventricular assist device (LVAD). The LVAD from Thoratec Corporation (Pleasanton, California), the Heart-
Mate LVAS (left ventricular assist system) XVE, helps the left ventricle of the heart pump blood throughout the body. A median 
sternotomy and cardiopulmonary bypass are required for access and implantation of the LVAD. The LVAD is implanted below 
the heart within the abdominal wall or peritoneal cavity. The LVAD is attached in parallel with the cardiovascular system. This 
leaves the heart connected to the circulatory system but provides the energy needed to propel blood throughout the body. 
The inflow cannula is anastomosed to the tip of the left ventricle so that blood is channeled into the device. An external con-
trol system triggers blood from the natural heart to fill the pump. A small motor drives the pump through an external battery-
powered control unit. A pusher plate forces a flexible polyurethane diaphragm upward and pressurizes the blood chamber. 
This motion propels blood through an outflow conduit and a graft that is attached to the ascending aorta. The ascending aorta 
is the main artery supplying oxygen-rich blood throughout the body. Valves located on either side of the pumping chamber of 
the device keep blood flowing in one direction only. For more information, see Thoratec Web site[1]. (From http://
www.heartfailure.org. [Used with permission.]). See Supplemental file for Uniform Resource Locator (URL) links for videos on 
implantation procedures of ventricular assist devices.Philosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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OMM (n = 18) were (46% vs 22%; P = .03) at 6 months
and (27% vs 11%; P = .02) at 12 months.
In the post-REMATCH study conducted between Novem-
ber 2001 and December 2005, the in-hospital mortality
rate was 27% for 280 patients who underwent HeartMate
XVE implantation as DT [13]. The causes of death were
infections with sepsis, right ventricular heart failure, and
multiorgan failure. The overall 1-year, 2-year and 3-year
survival rates were 56%, 31% and 17%, respectively. The
predictors of poor 1-year survival were cachexia, poor
nutrition, hematologic abnormalities, end-organ or right
ventricular dysfunction, and lack of inotropic support in
LVAD-DT. Stratification of LVAD-DT patients as having
low (n = 65), medium (n = 111), high (n = 28), or very
high (n = 18) risk on the basis of these predictors corre-
sponded with 1-year survival rates of 81%, 62%, 28%, and
11%, respectively [13].
The post-REMATCH study used a case-series design; there-
fore, it did not validate the survival advantage attributed
to LVAD in the subgroup analysis because it did not com-
pare 1-year survival with comparable low-risk or medium-
risk groups on OMM. Nonetheless, the excellent survival
rate attributed to LVAD-DT in the low-risk subgroup can
be similar to the survival rate with OMM in a similar
group of low-risk patients (i.e., clinical equipoise). There
has been an improvement in the overall survival rate after
the onset of heart failure of 12% per decade during the
past 5 decades [21]. The largest increase in survival is most
noticeable in low-risk heart failure patients because of
clinically significant advances in the development and uti-
lization of multiple-drug regimens for OMM. Currently,
the actual 3-year survival rate of risk-adjusted heart failure
patients is 71% on OMM [22] and compares favorably
with the survival rate of carefully selected low risk patients
after LVAD implantation [14].
Advances in medical technology have enabled rapid and
temporary application of short-term mechanical circula-
tory devices in emergency situations. Short-term mechan-
ical circulatory devices include, but are not limited to,
extracorporeal membrane oxygenation, percutaneous car-
diopulmonary bypass or percutaneous ventricular assist
devices. The short-term mechanical circulatory devices are
initiated as a bridge to long-term (also called bridge to
bridge) or a bridge to permanent surgical implantation of
LVAD [16,23]. Idelchik et al. reported a series of 18
patients with chronic end-stage heart failure who experi-
enced terminal hemodynamic collapse and underwent
emergency placement of a percutaneous ventricular assist
device (pVAD) (TandemHeart CardiacAssist Inc, Pitts-
burgh, Pennsylvania) as a bridge to long-term or perma-
nent surgical implantation of an LVAD [16]. In Idelchik et
al. study, patients survived pVAD and were successfully
bridged to a permanent LVAD: 4 patients received a Heart-
Mate XVE, 6 received a HeartMate II (Thoratec Corpora-
tion), 3 received a Jarvik 2000 (Jarvik Heart, Inc, New
York, New York), and 2 received a Novacor device. The
rate of survival with LVAD-DT was 73% at 30 days and
67% at 6 months. Gregoric et al. also reported emergent
placement of pVAD in a series of 9 end-stage heart-failure
patients [23]. The pVAD was a bridge to permanent surgi-
cal implantation of HeartMate II devices in 6 patients.
Neurologic complications
The use of LVAD-DT is associated with neurologic compli-
cations, such as stroke, transient ischemic attack, toxic-
metabolic encephalopathy, and cognitive dysfunction. A
stroke is a devastating complication for the LVAD patient.
It may be caused by an embolism from the device or a
hemorrhage into the brain parenchyma because of coagu-
lation disorders. The risk of stroke increases with the
length of time on LVAD support. The time on LVAD
before the occurrence of stroke can range from 30 to 500
days after implantation [11]. In the REMATCH trial,
major neurologic complications occurred at a high rate in
30 (44%) of the 68 LVAD-DT patients with the HeartMate
XVE compared with 4 (7%) of the 61 OMM patients [24].
In the INTrEPID trial, major neurologic complications
occurred at a high rate in 23 (62%) of the 37 LVAD-DT
patients with the Novacor device compared with 2 (11%)
of the 18 OMM patients [12]. Strokes accounted for 34%
of all deaths in LVAD-DT patients.
Of 124 patients with different ventricular assist devices
implanted at the University of Pittsburgh Medical Center,
31 (25%) experienced strokes, with a mean time on ven-
tricular assist device support of 228 days [25]. Of all
strokes, 66% occurred within 4 months after LVAD
implantation. Actuarial freedom from strokes at 6 months
was 75%, 64%, 63%, and 33% with the HeartMate device
(Thoratec Corporation), the Thoratec biventricular ven-
tricular assist device (Thoratec Corporation), the Thoratec
LVAD (Thoratec Corporation), and the Novacor device,
respectively. The type of implanted device influenced the
risk of stroke in LVAD. The risk of strokes in all patients
was increased by the occurrence of antecedent infections
irrespective of the device type. Long-term support with
these devices can cause a nonfocal decline of global cog-
nitive functioning in patients without a history of stroke,
which is possibly related to brain damage in the frontal
lobes [26].
Infections and sepsis
Serious infections and sepsis are the most common com-
plications after LVAD implantation and can occur in 18%
to 59% of patients [27]. In the REMATCH trial, freedom
from infections and sepsis in patients after implantation
with LVAD-DT was 58% at 1 year and 48% at 2 years [28].Philosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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Infections can involve any part of the device and other
organ sites, which increases the morbidity and mortality
in these patients. Infections and sepsis accounted for 31%
of all deaths in LVAD-DT patients over a 2-year interval in
the REMATCH trial [11]. The onset of infectious compli-
cations and sepsis in LVAD-DT decreased the 1-year and
2-year rates of survival to 39% and 8%, respectively. In the
INTrEPID trial, infections accounted for 24% of deaths in
patients with LVAD-DT [12]. Infections also appeared to
amplify the risk of acute strokes and permanent neuro-
logic events in patients with ventricular assist devices [25].
It can be inferred from the published reports of clinical
studies that LVAD-DT can add 12 to 24 months of survival
time to an average Medicare recipient, with an estimated
risk of 50% incidence of either serious neurologic or infec-
tious complications during that time (Figure 2). These
complications have consequences on QOL-adjusted sur-
vival and end-of-life trajectory for the average Medicare
recipient.
End-of-life trajectory and quality-of-life (QOL) adjusted survival with left ventricular assist device (LVAD) as a destination ther- apy (DT) Figure 2
End-of-life trajectory and quality-of-life (QOL) adjusted survival with left ventricular assist device (LVAD) as a 
destination therapy (DT). The effect of the use of an LVAD as DT (LVAD-DT) on quality of life (QOL) and survival in 
Medicare beneficiaries with chronic end-stage heart failure is evaluated by examining cumulative effects on multiple QOL 
domains (e.g., related to physical, mental, emotional, social, and financial areas), as well as the burden of disease and therapy on 
patients, caregivers, and family members. LVAD-DT had three possible effects (dotted lines) on QOL and end-of-life trajec-
tory, compared with those of medically treated patients (solid line): (A) Premature decline in QOL with shortened survival 
time because of postoperative complications and high in-hospital mortality rate (range 14%–27%) within 90 days after device 
implantation [11-13,15,16]. In this situation, survival time (S1) is shortened by several months compared with survival in the 
medically treated patient. The LVAD is electively inactivated at the end of life resulting in abrupt death. (B) No substantial 
change in QOL or survival time (S2) compared with that of the medically treated patient. The LVAD is electively inactivated at 
the end of life resulting in abrupt death. (C) The LVAD-DT alleviates limitations of physical functioning related to left heart fail-
ure, therefore explaining an initial enhancement of QOL. A gradual decline in QOL appears over a lengthened survival time 
(S3) because of high combined rates of late serious complications such as infections, sepsis, neurologic disabilities, and device 
malfunction or failure beyond 90 days of device implantation. The progression of comorbid conditions such as pulmonary 
hypertension, extra-cardiac end-organ disease and active malignancy also exacerbate terminal decline in the overall QOL. In 
this situation, average patient survival time after LVAD-DT can be lengthened by about 12 to 24 months, compared with that 
of the medically treated patient [11-13]. The LVAD is electively inactivated at the end of life resulting in abrupt death.Philosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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Device failure and replacement
Device malfunction or failure is defined as the inability of
the device system to maintain adequate circulatory sup-
port [11]. Most device malfunctions or failures are life
threatening but do not necessarily result in death. Device
replacement may be required in some patients. In the
REMATCH trial, 11 (16%) of the 68 LVAD-DT patients
died because of device failure [29]. Freedom from device
replacement was 87% at 1 year and 37% at 2 years [29]. In
a retrospective analysis of 46 patients who underwent
implantation with the HeartMate XVE (between July
2003, and March 2006), 13 of 15 patients had the device
either removed or replaced by ≥ 330 days postimplanta-
tion to avoid unexpected mechanical failures [30]. LVAD-
DT patients who experienced pump malfunction and sub-
sequently required replacement of their HeartMate XVE (a
first-generation pulsatile-flow pump) with HeartMate II
(a second-generation axial continuous-flow pump) had
increased morbidity and mortality after the surgical inter-
vention [31]. Pathologic and histologic examinations of
explanted HeartMate XVE (Figure 1) and Novacor devices
from patients reveal significant degradation of structural
integrity of bioprosthetic valves in the inflow and outflow
conduits as early as 3 month postimplantation [32]. The
bioprostheses valves in the inflow and outflow conduits
are critical for long-term durability of HeartMate XVE and
Novacor devices for DT. These bioprostheses valves are
exposed to the immune system and hemodynamic forces
soon after implantation. Over time, chronic inflamma-
tion along with mechanical forces weaken the valve cusps,
leading to tissue degeneration with cusp tears, hemor-
rhage, and thrombus deposition. These pathologic
changes can also explain the propensity of these devices to
increase the combined risk of neurologic and infectious
complications in implanted patients.
The HeartMate II device is implanted as a replacement of
the HeartMate XVE in an attempt to decrease the risk of
neurologic and infectious complications as well as device
malfunction or failure in LVAD-DT [31]. Nonetheless, the
continuous-flow LVAD-DT can accelerate the onset of
right heart pressure overload and heart failure in patients
with advanced heart failure [33]. The incidence of right
heart failure after LVAD implantation can be as high as
35%, and it decreases the 180-day survival rate of
implanted patients from 90% to 66% [34]. Continuous-
flow LVAD-DT abnormally augments diastolic blood flow
and pressure at the systemic capillary and arteriolar levels
in end organs such as the brain, kidneys, and gastrointes-
tinal tract during all phases of the cardiac cycle [33]. The
physiological effects of hyperperfusion that augment
diastolic blood flow and pressure can produce paradoxi-
cal vascular responses and end-organ injury. Stasis of arte-
rial blood flow distal to partial atherosclerotic obstruction
may increase the possibility of small-vessel occlusion.
Small-vessel occlusion in the brain can manifest with neu-
rological complications such as global cognitive decline
and stroke. The development of arteriovenous malforma-
tions is another serious complication of dampened pulsa-
tility and augmented diastolic blood flow and pressure by
continuous-flow LVAD-DT. LVAD-DT patients can
present with chronic gastrointestinal bleeding, which may
resolve only after device explantation and orthotopic car-
diac transplantation [35]. Therefore, in predicting end of
life for patients with LVAD, it is equally important to
determine the appropriateness of additional surgical
intervention and the timing for replacement of a failed
component or of the whole device because of serious mal-
function.
Quality of life
QOL domains include physical, psychological, social,
spiritual, and financial well-being. The Short-Form 36
Health Survey (SF-36) consists of 36 questions that meas-
ure physical and mental aspects of the patient's QOL [36].
The SF-36 evaluates the patient's own perspective of phys-
ical functioning, bodily pain, role limitations due to phys-
ical health problems, general health vitality, social
functioning, role limitations due to personal or emotional
problems, and mental health.
In the REMATCH trial, LVAD-DT patients had higher
scores than OMM patients in physical functioning (mean
score, 46 vs 21) and in emotional functioning (mean
score, 64 vs17) at 1-year follow-up [11]. However, the SF-
36 was completed by small subsets of survivors in the
LVAD-DT (n = 23) and OMM groups (n = 6) [11]. Therapy
with an LVAD is expected to alleviate symptoms and lim-
itations of physical functioning attributed to left heart fail-
ure. Nevertheless, the REMATCH trial did not address the
effect of LVAD-DT on other SF-36 scores (e.g., bodily pain,
social functioning, vitality, and mental health) and thus
did not provide a comprehensive evaluation of QOL in
survivors [11]. LVAD implantation can impose certain
restrictions on social functioning. The potential of device
failure requires patients to live close to a health care facil-
ity with the requisite expertise in LVAD technology [11].
Although patients can travel with the approval of their
physician, doing so can be hazardous because of the
potential development of emergency complications while
traveling.
In the REMATCH trial, the Beck Depression Inventory
(BDI) was used to measure the severity of depression in
patients [11]. BDI scores range from 0 (normal) to 64
(severely depressed). At 1-year follow-up, the mean BDI
scores were 8 and 13 for LVAD-DT (n = 23) and OMM (n
= 6) patients, respectively. The difference in BDI scores
between 8 and 13 on a 64-point scale is not clinically sig-
nificant, because neither score indicates severe depressionPhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
Page 7 of 15
(page number not for citation purposes)
in either the LVAD-DT or the OMM survivors. Patients
with an LVAD in situ had a higher incidence of anxiety dis-
orders and poorer psychological functioning than did
patients who had undergone transplantation or explanta-
tion of the devices [37].
Measuring the SF-36 or BDI scores before the occurrence
of major neurologic complications, infections, device
malfunction, or readmission to the hospital may not be
meaningful nor may it ascertain the real QOL in an LVAD-
DT patient. The patient's ability to perform activities of
daily living and self-care can be severely compromised
after a stroke, serious infection, or recent readmission to
the hospital. An LVAD can have considerable effects on a
patient's sense of self and perception of body image result-
ing in profound psychological sequelae for some patients
and their families [38]. It is not uncommon that psychiat-
ric symptoms, such as depression, anxiety, and posttrau-
matic stress disorders, are underdiagnosed and may be
undertreated in patients with LVAD-DT, which can affect
their overall QOL and survival [39].
Most patients with LVAD-DT died within 2 years of enroll-
ment in the REMATCH, INTrEPID, and post-REMATCH
clinical studies [11-13]. None of these studies provided
measures of the quality of end-of-life care or palliation in
the decedents in these clinical studies, which is surprising
given the high incidence of complications before death.
The physical health, levels of depression or anxiety, and
the rate of posttraumatic stress disorders in caregivers
were not assessed or reported in the LVAD-DT clinical
studies. Caregivers included anyone who provided infor-
mal and nonpaid care to the patients at home (e.g.,
spouses, adult children or grandchildren, family relatives,
significant others, or close friends). The quality of end-of-
life care and dying, as well as the quality of caregivers'
well-being, are considered important indicators of deliv-
ering patient-centered care and family satisfaction
[40,41].
Requirements of informed consent for LVAD-
DT
The legal and ethical foundation for informed consent is:
(1) the protection of patient autonomy and (2) the pro-
motion of informed rational medical care decisions. The
minimum requirements for informed consent include:
(1) a description of the proposed treatment, its risks, and
its benefits; (2) a description of alternate treatment
options, including their risks and benefits; and (3) the
voluntary granting of consent by a competent patient who
understands the information presented. If a patient has
impaired decision-making capacity, a legally designated
surrogate should substitute in the informed-consent proc-
ess [42].
The decision to undergo medical or surgical treatments is
expected to be based on an informed patient choice [43].
On the other hand, it has been reported that patients
undergoing invasive cardiac surgical procedures have a
poor understanding of their disease, their intervention,
and its complications making the attaining of true
informed consent difficult, despite their desire to be
informed of all risks [44]. LVAD-DT is a surgical proce-
dure with significant consequences for patients' end-of-
life care and trajectories (Figure 2) and with profound
effects on caregivers and their families. Therefore,
informed consent for LVAD-DT should include much
detailed discussion and evaluation of particular elements
before surgical implantation of the device (Table 1). It is
essential to conduct a balanced discussion of medical
management, palliation, and hospice care options, as well
as to discuss the surgical procedure itself. Patients, caregiv-
ers, and families must become familiar with LVAD-DT
complications, the progression of concurrent comorbid
conditions, and the development of new diseases that can
alter end-of-life trajectories (Figure 2). The possibility of
survival with serious neurologic disability and a high bur-
den of care require detailed explanation. Device-related
complications can affect both the estimated recovery time
before returning home, and the frequency of regular fol-
low-up visits or unplanned readmissions for inpatient
hospital care. This information can be presented by using
various communication tools to ensure that patients, car-
egivers, and family members fully understand and appre-
ciate the consequences of device implantation (Table 1).
Surgical implantation should not be initiated until the cli-
nician is convinced that the patient fully understands the
risks, benefits, and reasons for the decision. Clarity and
transparency in the consent process can help prevent sub-
sequent major conflicts in end-of-life decision after
implantation that require intervention by an institutional
ethics committee [45].
Scope of palliative care in LVAD-DT
The World Health Organization encourages the use of pal-
liative care in older persons with serious chronic progres-
sive diseases such as chronic end-stage heart failure [46].
The World Health Organization defines palliative care as
"an approach that improves the quality of life of patients
and their families facing the problems associated with life-
threatening illness, through the prevention and relief of
suffering by means of early identification and impeccable
assessment and treatment of pain and other problems,
physical, psychosocial and spiritual" [47]. The World
Health Organization palliative care criterion of neither
hastening nor postponing death prevents the categoriza-
tion of LVAD-DT as a form of palliative care. However,
this criterion does not preclude providing palliative care
in conjunction with life-prolonging therapy such as
LVAD-DT. Palliative care focuses on managing intractablePhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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Table 1: Requirements for informed consent for left ventricular assist device as destination therapy
Participants
• Patient
• Surrogate decision maker or medical power of attorney
• Caregiver (spouse, adult child, significant other, etc.)
• Primary care physician
• Palliative care specialist
• Cardiology specialist
• Cardiovascular surgical specialist
• Clergy
• Social services
Information content
• Description of end-stage heart failure disease and natural history
• Description of optimal medical management
• Description of palliative care and symptom management
• Description of hospice services
• Description of surgical procedure for device implantation
• Description of benefits from device implantation over optimal medical management
• Description of complications after device implantation
 Short-term operative death or complications
 Expected time of hospitalization and recovery from the surgical procedure
 Expected survival time after device implantation
 Expected quality of life (e.g., physical, psychological, social, and financial)
 Long-term complications
❍ Device-related complications
▪Complications after open-heart surgery
▪Neurologic complications
▪Infections
▪Device troubleshooting
▪Device malfunction and failure
▪Pain
▪Noise and sleep-related disorder
❍ Concurrent or new clinically significant comorbid conditions and diseases
 Notification or training of local hospital personnel and doctors
 Transfer to regional hospitals for inpatient specialized medical care
 Frequency of regular follow-up visits
 Frequency of inpatient readmissions
 Development of new intractable symptoms from right heart failure
 Advance care planning and documentation 
(e.g., in event of a stroke, serious infection, device replacement, loss of decision-making capacity, or disseminated malignancy)
 Anticipated end-of-life trajectories
 Palliative and hospice care with or without device implantation
 Device deactivation and death planning (when and where to "turn off" the device)
 Device procedures in end-of-life organ donation
• Description of short-term and long-term medical care costs with or without device implantation
• Caregiver burden after device implantation
 Physical
 Psychological
 Social
 Cultural
 Financial
 Daily life activities and work or employment
Communication tools
• Face-to-face interviews
• Device patients' support groups
• Caregivers' support groups
• Audiovisual mediaPhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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symptoms, preserving QOL, and communicating effec-
tively with patients, caregivers, and families on end-of-life
concerns. When palliative-care teams support the physi-
cal, emotional, and spiritual well-being of patients, car-
egivers, and their families, there is greater satisfaction with
the overall quality of care [40,48]. The burden of unre-
lieved generalized pain, physical symptoms, and psycho-
logical symptoms has a negative impact on the QOL of
patients with chronic end-stage heart failure [49]. Most of
these patients express meaningful preferences about
improving the quality versus the length of life [50]. Palli-
ative care within a multidisciplinary team approach
enhances the quality of end-of-life and shared decision
making in chronic end-stage heart failure [40,48,51].
Palliative care can play an important role in conjunction
with LVAD-DT in chronic end-stage heart failure (Table
2). LVAD-DT patients are often 65 years or older and may
have clinically significant comorbid conditions. The early
involvement of palliative-care specialists in the consent
process for LVAD-DT is highly recommended because of
the extremely invasive nature of LVAD-DT, the subse-
quent limitations on QOL-adjusted survival, and postim-
plantation alterations in end-of-life trajectories (Figure 2).
Clinicians in medical and surgical specialties involved
with the implantation and management of LVAD-DT may
not be familiar with the full spectrum of available pallia-
tive-care options and the benefits (Table 2). Clinicians
experienced in palliative care can best present the pallia-
tive-care options to patients, caregivers, and family mem-
bers [52]. Therefore, the patient care team should include
palliative care specialists early in the decision-making
process well before implantation of LVAD-DT.
If a patient chooses to proceed with LVAD-DT after an
informed consent discussion, palliative care specialists
can continue to provide medical care within the multidis-
ciplinary team approach. Continuity of palliative care is
essential for the support of patients, caregivers, and family
members and for their overall satisfaction with quality of
• Electronic media (Web sites)
• Printed media (brochures)
Verification of understanding of the relevant information 
(i.e., the patient and the caregiver should paraphrase the disclosed information)
• Nature of the patient's medical condition
• Nature and purpose of the surgical procedure for device implantation
• Benefits and risks of device implantation
• Benefits and risks of optimal medical management
• Caregiver burden
• Anticipated changes in end-of-life trajectories
• Palliative and hospice care access with or without device implantation
• End-of-life care planning
• Mode of dying and death
Validation of first-person (patient) informed decision making
• Patient acknowledges seriousness of medical condition and likely consequences
• Patient compares medical and device therapies and consequences of each option
• Patient offers reasons for not selecting medical therapy as an option
• Patient offers reasons for selecting device implantation as an option
Table 1: Requirements for informed consent for left ventricular assist device as destination therapy (Continued)
Table 2: Benefits of early palliative care in candidates considered for left ventricular assist device (LVAD) as destination therapy (DT).
• Apply early in the course of illness, in conjunction with other life-prolonging therapies to help patient better understand and manage new 
distressing symptoms and clinical complications
• Provide relief from pain and other distressing symptoms
• Enhance patient's quality of life
• Integrate the psychological and spiritual aspects of patient care
• Offer a support system to help patients live as actively as possible until death
• Offer a support system to help caregivers and family members cope during the patient's illness
• Affirm life, and regard dying as a normal process
• Intend neither to hasten nor postpone death
• Offer a support system to help caregivers and families with the grief reaction, including bereavement counseling after device deactivation and 
deathPhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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medical care [40]. Palliative care specialists can intervene
and counsel during follow-up as new physical, psycholog-
ical and social problems develop in LVAD-DT patients.
Furthermore, patients who initially agree to LVAD-DT
may eventually decide to discontinue it. Patients may ask
that such therapy be withdrawn in the event of a debilitat-
ing stroke, a severe infection, incapacitation by a comor-
bid condition, or the need for a second major surgery to
replace device components [45]. Advance-care planning
with palliative care specialists can smooth the transition
to elective deactivation or the "turning off" of the device
to allow progression to death [53].
Caregiver burden
An important dimension of the informed-consent process
is the effect of LVAD-DT on caregivers. A portable LVAD
facilitates the discharge of patients from the hospital.
However, discharging patients to go home can also
increase physical, psychological, and financial strains on
caregivers [54]. Caregivers need high levels of vigilance
and education about these devices to detect early compli-
cations and troubleshoot device malfunctions [11]. Car-
egivers tend to worry more about device-related problems
(e.g., malfunctioning, pain, infection, and stroke) than do
the patients themselves [55]. Most of device malfunctions
or failures that occur at home are frightening to caregivers.
Caregivers are informally recruited to provide continuous
care at home and to accompany patients to regular visits
or unplanned hospital readmissions.
The intensity of long-term care required in different
comorbid conditions determines the severity of physical
and psychological consequences on caregivers [56]. The
use of temporary or permanent, mechanical, life-support
devices has profound physical and psychological conse-
quences on caregivers. Mechanical ventilators are much
more common than mechanical circulatory devices in
clinical practice. However, there appear to be similarities
in the long-term psychological and physical consequences
for caregivers from the prolonged use of mechanical ven-
tilators and mechanical circulatory devices. For example,
caregivers of survivors on mechanical ventilators experi-
ence severe depression, anxiety, and posttraumatic stress
disorders lasting as long as 12 months [57]. These disor-
ders are incapacitating and prevent more than 20% of car-
egivers from returning to their normal daily life activities
or previous employment. Poor physical health may also
develop in caregivers, which can exacerbate depression
[56]. Mechanical circulatory devices used as bridge or des-
tination therapy result in a similarly high incidence of
depression, anxiety, and posttraumatic stress disorders in
caregivers [55,58].
LVAD-DT recipients are typically older and are therefore
more likely to have spouses as caregivers who have health
concerns of their own. The intensity of care required for
LVAD patients at home can exacerbate physical health
problems in caregivers. Feeling overloaded with responsi-
bilities often produces psychological distress in the car-
egiver that can manifest as severe depression and
posttraumatic stress disorder. Younger caregivers who
provide home care are also at risk of developing financial
difficulties if they are unable to continue working. Thus, a
discussion of the potential effects on the physical health
and the psychological, social, and financial well-being of
caregivers should be an integral part of the decision-mak-
ing process in LVAD-DT.
Device costs and financial burden
In the REMATCH trial, the average total hospital cost of
surgical implantation of LVAD in hospital survivors and
nonsurvivors was $159,271 and $315,015, respectively
[59]. The average cost for each hospital readmission for an
LVAD recipient was $105,326. Nonetheless, the post-
REMATCH study reported a 40% decrease in the average
total hospital cost of LVAD-DT implantation to $128,084
per recipient in a select 23 of the 280 patients from
$210,187 per recipient in 52 of 68 patients in the
REMATCH trial [60]. Single centers have reported a much
higher average total hospital cost per recipient for LVAD
implantation ($197,957) than for cardiac transplantation
($151,646) [61]. The average cost per quality-adjusted
life-year was estimated at $312,551 in an economic eval-
uation of 6 studies (1 randomized control trial, 1 case
series, and 4 case reports between 1995 and 2003) that
reported improved survival and QOL with LVAD-DT in
chronic end-stage heart failure [62]. One US study
reported a cost per quality-adjusted life-year of $36,255 to
$60,057 for LVAD-DT [63]. The wide discrepancy in
reported cost-effectiveness requires further analyses
undertaken alongside randomized controlled trials and
use of OMM and second-generation and third-generation
ventricular assist devices.
The costs of short-term and long-term medical care
required after device implantation should be explained in
detail to patients. Regular office visits, unplanned visits to
emergency rooms or hospital readmissions because of
complications, device malfunctions, or unrelated illness
can increase the financial burden for patients and caregiv-
ers alike. Patients residing in rural communities may have
to travel long distances for follow-up visits at specialized
centers. These financial implications must be explored
with patients, caregivers, and family members during the
consent process.
Presumed and surrogate consent in emergency 
situations
We have outlined the prerequisite conditions for a first-
person (the patient) voluntary informed consent forPhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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LVAD-DT. Advances in medical technology have enabled
rapid and temporary application of short-term mechani-
cal circulatory devices such as pVAD in emergency situa-
tions as a bridge to permanent implantation of an LVAD
[16,23]. The feasibility of this technology in clinical prac-
tice raises a new ethical question: should presumed or sur-
rogate consent substitute for first-person consent in
emergency situations to authorize the use of these tempo-
rary short-term mechanical circulatory devices in patients
with chronic end-stage heart failure? It has been argued
that only first-person consent should permit LVAD-DT in
chronic end-stage heart failure [64]. Three reasons have
been proposed to justify first-person consent over pre-
sumed or surrogate consent: (1) the respect for patient
autonomy, (2) the availability of less-burdensome end-
of-life therapies, and (3) the noncurative elective nature of
LVAD-DT as an end-of-life therapy. Presumed consent is
the type of consent most relevant to procedures or inter-
ventions performed in emergency situations. Presumed
consent arises when there are good empiric grounds for
claiming that patients would consent if they could
respond when asked [65]. Ideally, the relevant data would
come from past choices that an individual patient had
made in similar circumstances. The presumed consent
approach is not applicable for LVAD-DT, however,
because there are too many contingent variables (e.g., age,
overall health, religious convictions, and financial
resources) that influence a reasonable person's decision
about this type of treatment. A reasonable person might
choose to refuse a noncurative and burdensome treatment
for a fatal disease. By this definition, the initiation of a
short-term mechanical circulatory device as a bridge to
permanent implantation of an LVAD would also qualify
for first-person consent. Compare the following 2 emer-
gency decision-making positions:
(1) According to position "0" (P0), in the absence of first-
person consent, clinicians should use only those procedures
(e.g., temporary circulatory support with cardiac medica-
tions only) that are reasonable to use and are not reasona-
ble to not use.
(2) According to position "1" (P1), in the absence of first-
person consent, clinicians should use all procedures (e.g.,
temporary circulatory support with cardiac medications
and short-term mechanical circulatory devices as a bridge
to permanent implantation of an LVAD) that are reasona-
ble to use, even if it is equally reasonable to not use them.
There are 3 ethical considerations to consider in compar-
ing P0 and P1: (1) patient-centered moral reasons (i.e., the
promotion of the patient's best interests), (2) justice (i.e.,
the minimum care owed to a person in society while
ensuring equality in distribution), and (3) utility (i.e., the
promotion of the greatest benefit to the greatest number
of individuals while inflicting the least amount of harm).
P0 and P1 and the best interests of the patient
Are P0 and P1 equal in terms of respect for the patient's
best interests when the patient's preferences are not
known? In the absence of a well-informed surrogate or an
advance directive, the clinician is just as likely to contra-
dict what the patient would choose by going ahead with a
procedure that is reasonable to not perform as it would be by
going ahead with a procedure that is reasonable to perform.
This premise is especially true for patients who are candi-
dates for LVAD-DT because the patients will likely be of
advanced age and in refractory chronic end-stage heart
failure with other clinically significant comorbid condi-
tions that preclude eligibility for cardiac transplantation.
It is ethically, medically, and legally reasonable to with-
hold artificial life-sustaining treatments in a patient with
a progressive terminal disease so as to allow a peaceful
death [66].
There is a difference between P0 and P1 from a patient-cen-
tered moral perspective when the patient's preferences are
not known. If, in an emergency situation, the clinician
chose P1, but the treatment turned out to not be what the
patient wanted, then this decision could be reversed. The
temporary short-term mechanical circulatory device could
be turned off. However, if P0 was chosen, the end result
would not be reversible. Therefore, it can be postulated
that voluntary withdrawal of life-support treatment may
be morally equivalent to the refusal to initially begin that
treatment. However, it does not follow that the patient
and his or her family after P1 would find it just as easy to
deal with treatment withdrawal as they would with treat-
ment refusal initially (P0). It may be psychologically
impossible for most patients to go through the process of
shutting off short-term mechanical circulatory devices or
deactivating ventricular assist devices including an LVAD
after the device has been initiated, even if they might have
elected to not have the device in the first place had they
been afforded the opportunity to make that decision
[45,67,68]. Hence, the clinician risks putting the patient
or surrogate in the difficult and distressing position of
having to make a decision that they never wanted to have
to make. This type of decision can also create substantial
cultural and religious conflicts and guilt feelings for surro-
gates and families.
Organ donation can also influence the process of deacti-
vating mechanical circulatory devices and ventricular
assist devices [69,70]. The Uniform Anatomical Gift Act
was revised in 2006 to mandate the evaluation of all
patients for end-of-life organ donation before the with-
drawal of life support systems such as mechanical circula-
tory devices [71]. After the initial deactivation of aPhilosophy, Ethics, and Humanities in Medicine 2008, 3:20 http://www.peh-med.com/content/3/1/20
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mechanical circulatory device for a declaration of death,
the device may be reactivated in a donor for artificial cir-
culatory support in order to preserve organs for transplan-
tation. Concurrently, medications may have to be
administered to suppress reanimation when the mechan-
ical circulatory device is reactivated in a donor [72]. The
initiation of mechanical circulatory devices as an end-of-
life treatment and their subsequent conversion for organ
preservation and donation without first-person consent
poses serious cultural, religious, and perhaps legal dilem-
mas for clinicians, surrogates, and families.
P0 and P1, justice, and utility
In emergency situations in which the clinician has no idea
of the patient's preferences, withholding short-term
mechanical circulatory devices and LVAD-DT would not
seem to violate any duty to the patient. The more
resources required for a specific treatment, the less plausi-
ble it is for that treatment to constitute the basic care to
which all persons are entitled in a fair and equitable dis-
tribution of health care resources. There is no reason to
suggest that withholding mechanical circulatory devices
and LVAD-DT would constitute an injustice to patients
who have not elected such treatment.
If P0 and P1 are equally just in LVAD-DT and neither leads
to a substantial advantage for maximizing the good for a
particular patient, then these positions will differ on util-
itarian grounds. In general, P0 is clearly efficient. In con-
trast, P1 entails an asymmetrical use of resources without
a proportional increase in benefits for the average patient.
This discrepancy is the best reason for support of the need
for first-person consent for LVAD-DT [64]. On a societal
level, it is not cost-effective to use limited health care
resources for a treatment whose benefits are comparable
only to those resulting from not treating the patient, who
might reasonably have chosen to forgo the treatment if
given the choice [73].
Unlike P1, P0 eliminates potential financial reasons that
might influence the decision-making process. Although at
least one report suggests that LVAD therapy may cause a
loss of revenue for health care facilities [61], participation
in this new technology can have academic rewards and
community prestige. Consistently applying P0 rather than
P1 could also curb future research and development of
short-term and long-term mechanical circulatory devices
in clinical practice. It can be equally argued that surrogate
consent should not replace first-person consent when
short-term mechanical circulatory devices are used for
temporary support in emergency situations as a bridge to
permanent implantation of an LVAD. In an emergency sit-
uation, it may be difficult if not impossible to fulfill the
prerequisite conditions outlined in Table 1 to ensure that
surrogate consent is an informed process and in the
patient's best interest.
Conclusion
Compared with OMM, LVAD-DT can prolong the survival
of recipients in chronic end-stage heart failure. Overall
QOL can also be adversely affected in some recipients
because of infections, serious neurologic disabilities, or
device malfunction. LVAD-DT alters end-of-life trajecto-
ries. Caregivers can experience physical, psychological,
and financial burdens after this type of treatment. There-
fore, we advocate early utilization of a palliative care
approach and outline the following conditions for
informed consent: (1) direct participation of a multidisci-
plinary care team that includes palliative care specialists,
(2) a concise plan of care for anticipated device-related
complications, (3) careful surveillance and counseling for
caregiver burden, (4) advance care planning for antici-
pated end-of-life trajectories and timing of the device's
deactivation, and (5) discussion about the long-term
financial burden on patients, families, and caregivers. In
the absence of first-person consent, presumed consent or
surrogate consent should be used cautiously before initi-
ating short-term mechanical circulatory devices in emer-
gency situations as a bridge to permanent implantation of
LVAD in chronic end-stage heart failure. Future clinical
studies of LVAD-DT should include measures of recipi-
ents' quality of end-of-life care and caregivers' burden.
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